{"id":"epha2","name":"EphA2 receptor","symbol":"EPHA2","route":"/targets/epha2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3386","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142627","uniprot":"https://www.uniprot.org/uniprotkb/P29317/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P29317","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2068","open-targets":"https://platform.opentargets.org/target/ENSG00000142627","civic":"https://civicdb.org/genes/1969/summary","oncokb":"https://www.oncokb.org/gene/EPHA2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EPHA2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=EPHA2","depmap":"https://depmap.org/portal/gene/EPHA2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000142627-EPHA2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1969","omim":"https://www.omim.org/entry/176946"}],"products":[{"id":"dasatinib","name":"Dasatinib","status":"approved","modality":"Small-molecule kinase inhibitor (BCR::ABL1, SRC)","route":"/drugs/dasatinib/"}],"trials":[{"id":"nct04971226","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","nct":"NCT04971226","phase":"3","status":"active"},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","nct":"NCT02883049","phase":"3","status":"completed"},{"id":"ready-dasatinib","name":"READY","nct":"NCT00744497","phase":"3","status":"negative"},{"id":"dasision","name":"DASISION","nct":"NCT00481247","phase":"3","status":"positive"},{"id":"d-alba","name":"D-ALBA (GIMEMA LAL2116)","nct":"NCT02744768","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"}],"pathways":[],"companies":["bms","conjustar-biologics"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}